COVID-19: Two Vaccines Currently Under Trial Have 90% Efficacy – FG

The Federal Government of Nigeria has stated that COVID-19 would soon be something to be less worried about in the country and this is due to the fact that two vaccines under trial have more than 90% viability to end the disease.

Advertisements

Boss Mustapha, the Secretary to the Government of the Federation and chairman of the Presidential Task Force on COVID-19 stated this on Tuesday during an occasion held in Abuja to celebrate the 2020 World AIDS Day with the theme, ‘Worldwide Solidarity, Shared Responsibility.’

⇒Join us on Telegram for more Sure and Accurate football-winning tips every day...click here

Mustapha likewise asked Nigerians to play it safe to try not to be infected with the Covid.

“As Chairman of the Presidential Task Force on COVID-19, we have intentionally found a way to guarantee that as a country our residents do the needful to abstain from being infected or infecting others with COVID-19 and with two vaccines under trial conceivably having more than 90% viability, I believe that eventually there will be a culmination of current circumstances,” Mustapha said.

Advertisements

He added, “drawing from this, it is additionally adept that Nigeria has picked a theme: “Joined to end AIDS amidst COVID – 19: Get tried”.

“Nigeria as a country adjusted completely with the worldwide fortitude and shared duty, which expects us to see worldwide wellbeing reactions, including the AIDS reaction, in another way.”

In the interim, the Nigeria Center for Disease Control (NCDC) on Tuesday night declared 281 new cases of COVID-19 in the country.

The 281 new infections now bring the total number of cases in the country to 67,838.

About Esther Talk

Esther is a seasoned writer and broadcast journalist with years of experience in both media, print, and broadcast journalism. A graduate of Sociology/Anthropology with a passion for editing and journalism.

View all posts by Esther Talk

Leave a Reply

Your email address will not be published. Required fields are marked *